Total : 21 View more »
Biotechnology company Antigenics Inc. said Friday it will not seek approval for a potential kidney cancer treatment after a European advisory committee recommended against approving the drug candidate.
A negative vote of the CHMP indicating this opinion was verbally conveyed to Antigenics and announced in a press release issued on October 21, 2009.
http://www.biospace.com/news_story.aspx?StoryID=163547&full=1
Antigenics, Inc. (NASDAQ: AGEN) today indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=10001
Antigenics (AGEN)Q3 2009 Earnings CallOctober 29, 2009 11:00 AM ETComplete
http://seekingalpha.com/article/169934-antigenics-q3-2009-earnings-call-transcript?source=feed
Total : 29 View more »
NEW DELHI, INDIA, Nov 23, 2009 (MARKETWIRE via COMTEX) --
All ten sectors ended in the red today led by technology, financial and energy sectors. Consumer staples and healthcare sectors registered the least losses. This drove us to do research on the following 6 stocks DENTSPLY International Inc. (NASDAQ: XRAY), PAETEC Holding Corp. (NASDAQ: PAET), Antigenics Inc. (NASDAQ: AGEN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Alkermes Inc. (NASDAQ: ALKS) and Biogen Idec Inc. (NASDAQ: BIIB). You can now access these research reports with many others by signing up at Analyst Choice.
To see if our analysts believe you should BUY, SELL or HOLD these six stocks sign up at Analyst Choice.
The following are exempts of the above reports:
-- XRAY seems to be weathering the downturn well.
-- PAETEC is well positioned with management debt, financial strength
and...
-- In August, Antigenics raised $20 million through two separate private
placements of common stock and...
-- Cubist's strong top and bottom line results have been achieved in an
environment that has been tough for many branded pharmaceuticals.
-- Alkermes performed reasonable in this economic downturn. Its financial
and operating results remain strong and...
-- During the third quarter BIIB drove a clear acceleration of TYSABRI
patient growth that puts the drug on a blockbuster run-rate.
You can now access these full research reports along with many others by signing up for free at Analyst Choice or www.analystchoice.com.
About Analyst Choice:
Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. While the world economy undergoes enormous pressure and unprecedented actions are been taken to avoid the worst and boost the shrinking global economic growth, our analysts brings you a bird's eye view of how the big players in the different key sectors and industries of the NASDAQ and NYSE, are coping. Sign up now by visiting the following link. http://www.analystchoice.com/
AnalystChoice.com is an independent financial research portal and as such has not received any compensation by any of the above mentioned companies.
SOURCE: Analyst Choice
Tags: consumer debt economic growth economy editors energy environment equity healthcare investment opinion nasdaq note nyse pharmaceuticals research technology
Companies: Alkermes, Inc. (ALKS), Antigenics, Inc. (AGEN), Biogen Idec Inc (BIIB), Cubist Pharmaceuticals, Inc. (CBST), DENTSPLY International, Inc. (XRAY), PAETEC Holding Corp (PAET)
LONDON, Nov 20, 2009 (BUSINESS WIRE) --
Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer). A negative vote of the CHMP indicating this opinion was verbally conveyed to Antigenics and announced in a press release issued on October 21, 2009.
Based on this opinion, Antigenics has decided to withdraw its Marketing Authorization Application and to evaluate its options going forward, including a potential re-filing at a later date. A decision to re-file would be dependent on outcomes following meetings with health authorities in individual European countries and with the EMEA, as well as based on further accumulation and review of clinical data. In the meantime, Antigenics is hopeful that it will be in a position to supply Oncophage, as requested, under a named patient program in Europe, in addition to its ongoing commercial efforts in Russia and named patient programs elsewhere globally.
"Despite the CHMP's negative decision, we continue to believe that the evidence supports Oncophage as a treatment option for a well defined patient group with localized renal cell carcinoma. It is for this reason that we continue our commitment to bring Oncophage to patients who can potentially benefit; these include patients with earlier stage kidney cancer where there are no available treatments," commented Garo Armen, Chief Executive of Antigenics. "In addition to our ongoing clinical programs in glioma, we will investigate the use of Oncophage in combination with other cancer treatments with a strict focus on working efficiently and preserving our capital."
No medication has been approved in Europe or the United States for the treatment of adjuvant kidney cancer, a disease characterized by a high risk of recurrence.
About Oncophage
Antigenics has treated nearly 800 patients in clinical trials throughout North America and Europe with Oncophage produced in their commercial facility located in Lexington, Massachusetts. Studies with Oncophage have demonstrated efficacy signals in multiple cancers, including melanoma, glioma, colorectal, pancreatic, renal cell carcinoma, gastric cancer and non-Hodgkins lymphoma.
In April 2008, Oncophage was approved in Russia for the adjuvant treatment of kidney cancer patients at intermediate-risk for disease recurrence. Pre-commercial launch activities are ongoing.
Derived from each individual's tumor, Oncophage contains the 'antigenic fingerprint' of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. Oncophage is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy. Oncophage has been studied in Phase 3 clinical trials for the treatment of kidney cancer and metastatic melanoma and is currently being investigated in Phase 2 trials in recurrent and newly diagnosed glioma.
Oncophage received fast track and orphan drug designations from the US Food and Drug Administration (FDA) for both kidney cancer and metastatic melanoma as well as orphan drug designation from the EMEA for kidney cancer. In 2009, Oncophage also received orphan drug designations from the FDA and EMEA for glioma.
In April 2009, the World Vaccine Congress named Oncophage as the best therapeutic vaccine.
About Renal Cell Carcinoma
Renal cell carcinoma is the most common type of kidney cancer, accounting for almost 90 percent of all kidney tumors. According to a report in the Annals of Oncology, there were more than 63,000 new cases of RCC diagnosed in 2006 along with 26,000 deaths related to the disease.(1) Despite earlier detection, patients with locally advanced disease face a poor prognosis, with a 5-year survival rate of approximately 50 percent due to recurrence of disease. Currently, no approved therapies exist in the EU for use in localized disease.
About Antigenics
Antigenics (NASDAQ: AGEN) is a biotechnology company working to develop treatments for cancers and infectious diseases. For more information, please visit www.antigenics.com.
This press release contains forward-looking statements regarding Antigenics' business and plans, including statements regarding Antigenics' regulatory strategies. These forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties, include without limitation, opinions and decisions of regulatory authorities, clinical data results, the availability of resources, and the risk and uncertainties described in Antigenics' SEC reports filed under the Securities Exchange Act of 1934, including those mentioned in the Risk Factors section of Antigenics' Quarterly Report on Form 10Q for the quarter ended September 30, 2009. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.
(1) Ferlay, J. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology.18(3):581-92. March 2007.
SOURCE: Antigenics Inc.
Antigenics Inc. Media: Brad Miles, 212-477-9007 ext 17 or Investors: Shalini Sharp, 800-962-2436
Tags: accounting biotechnology business cancer clinical commercial congress disease europe fda health marketing massachusetts nasdaq north america products russia sec securities track vaccine
Companies: Antigenics, Inc. (AGEN)
Nov 17, 2009 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend, our proprietary pattern recognition system, called a Downtrend for Antigenics (NASDAQ:AGEN) on October 21, 2009 at $1.29.
Since then, Antigenics has returned 24.1% as of today's recent price of $0.98. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq profit securities trial
Companies: Antigenics, Inc. (AGEN)
Nov 11, 2009 (SmarTrend(R) Research Reports via COMTEX) --
SmarTrend, the proprietary pattern recognition system, has made available a free sample copy of our premium research report on (NASDAQ:AGEN) at http://www.mysmartrend.com/research/
SmarTrend, our proprietary pattern recognition system, called a Downtrend for Antigenics (NASDAQ:AGEN) on October 21, 2009 at $1.29. Since then, Antigenics has returned 16.3% as of today's recent price of $1.08.
Want access to these reports and real time alerts? Go to www.tradethetrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nasdaq research securities trial
Companies: Antigenics, Inc. (AGEN)
Total : 71 View more »
The Brain Tumor Research Center at the University of California, San Francisco, has initiated a Phase 2 clinical trial evaluating the effect of Oncophage on overall survival in patients with recurrent glioma. View press release
SAN DIEGO, Calif. - - ICON Group International Ltd., today released studies on labor productivity and financial benchmarks for Antigenics Incorporated (NAS: AGEN).
http://www.icongrouponline.com/pr/Antigenics_Incorporated_US/PR.html
Still working the hard way? If you're editing, writing, or typesetting in Microsoft Word, our program add-ins will save you time and money and improve the editorial and typographical quality of every project.
Antigenics' project involved translation to support the clinical trial of the company’s personalized cancer vaccine. They required immediate translation of case report form (CRF) data for an upcoming interim analysis.
Total : 292 View more »
Biotechnology company developing cancer vaccines and other treatments for cancer and infectious diseases
Get the latest AGEN - Antigenics Incorporated stock market performance data. TheStreet is the source for financial market news, trading stock, quotes, and personal finance advice.
Stay informed on the latest Antigenics Incorporated news. TheStreet is the source for financial market and Wall Street news, trading stock and personal finance advice.
http://www.thestreet.com/topic/5933/antigenics-incorporated.html
Dr. Levitsky is Professor of Oncology, Medicine & Urology at The Sidney Kimmel ... Antigenics, Incorporated (AGEN)